Skip to main content
SpringerLink
Log in

Prucalopride: a guide to its use in chronic constipation

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

References

  1. Frampton JE. Prucalopride. Drugs 2009; 69(17): 2463–76

    Article  PubMed  CAS  Google Scholar 

  2. Johanson JF. Review of the treatment options for chronic constipation. MedGenMed 2007; 9: 25

    PubMed  Google Scholar 

  3. De Maeyer JH, Lefebvre RA, Schuurkes JA, et al. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008 Feb; 20(2): 99–112

    Article  PubMed  Google Scholar 

  4. European Medicines Agency. Resolor (prucalopride) tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Apr 23]

  5. Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation: a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009 Feb 1; 29(3): 315–28

    Article  PubMed  CAS  Google Scholar 

  6. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009 Mar; 58(3): 357–65

    Article  PubMed  CAS  Google Scholar 

  7. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008 May 29; 358(22): 2344–54

    Article  PubMed  CAS  Google Scholar 

  8. Tack J, Ausma J, Kerstens R, et al. Efficacy and safety of 12-week treatment with prucalopride in patients with severe chronic constipation: combined results of 3 identical, double-blind, placebo-controlled trials [abstract]. XXIst Belgian Week of Gastroenterology; 2009 Feb 12–14; Antwerp

  9. Tack J, Dubois D, Kerstens R, et al. PAC-QOL results from 3 identical randomized placebo-controlled trials with prucalopride in patients with severe chronic constipatiion [abstract no. T1259]. Gastroenterology 2009; 136(4 Suppl. 1): A533

    Google Scholar 

  10. Van Outryve MJ, Beyens G, Kerstens R, et al. Long term follow up study of oral prucalopride (Resolor®) administered to patients with chronic constipation [abstract no. T1400]. Gastroenterology 2008 Apr; 134(4 Suppl. 1): A547

    Google Scholar 

  11. Camilleri M, Beyens G, Kerstens R, et al. Long-term follow-up of safety and satisfaction with bowel function in response to oral prucalopride in patients with chronic constipation [abstract no. 160]. Gastroenterology 2009; 136(5 Suppl. 1): A31

    Google Scholar 

  12. Tack JF, Ausma J, Kerstens R, et al. Safety and tolerability of prucalopride (Resolor®) in patients with chronic constipation: pooled data from three pivotal phase III studies [abstract no. T1322]. Gastroenterology 2008 Apr; 134(4 Suppl. 1): A530

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prucalopride: a guide to its use in chronic constipation. Drugs Ther. Perspect 26, 1–4 (2010). https://doi.org/10.2165/11205150-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11205150-000000000-00000

Search

Navigation